Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

Abstract: Methods of treating trypanosomiasis and, particularly, methods of treating trypanosomiasis using neohesperidin dihydrochalcone. Such methods of treatment are useful in, for example, animals selected from the group consisting of cattle, sheep, pigs, goats, horses, and camels.

Abstract: Disclosed herein are methods of reducing or preventing thrombocytopenia, in a clinically relevant manner, that is caused by chemotherapy or radiation therapy by administering plinabulin to a subject.

Abstract: Provided herein is a method for extracting polysaccharides, for example, ?-glucan and sodium alginate, from a sample including a botanical product. The extraction can be carried out using a microwave assisted dual-solvent extraction followed by one or more membrane filtration steps.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: The present invention is directed to various compounds, compositions, and methods for treating bacterial infections such as urinary tract infections.

Abstract: There is provided a method for efficiently produce hydroxypropyl methyl cellulose acetate succinate (HPMCAS) having excellent flowability, where acetic acid in a reaction product mixture subjected to a wash and recovery step can be reduced. More specifically, there is provided a method for producing HPMCAS including an esterification step of esterifying hydroxypropyl methyl cellulose (HPMC) with acetic anhydride and succinic anhydride in acetic acid as a solvent to obtain a reaction product solution containing HPMCAS; a water addition step of adding water to the reaction product solution to obtain a water-added reaction product solution; an acetic acid removal step of removing at least a portion of both the solvent acetic acid and acetic acid derived from the acetic anhydride from the water-added reaction product solution to obtain a mixture having an acetic acid content reduced; and a wash and recovery step of washing the mixture and recovering the HPMCAS.

Abstract: The invention is directed to an intratumor injectable formulation, a method of making the intratumor injectable formulation and a method of treating a malignant mass in a mammal by administering the injectable formulation directly into the malignant mass. The injectable intratumor formulation may be an emulsion, solution or suspension, all of which comprise a therapeutically effective amount of a basic chemotherapeutic drug dissolved or suspended in a biocompatible carrier, wherein the basic chemotherapeutic drug is an anthracycline base, a vina alkaloid base, an eribulin base or an alkylating agent base.

Abstract: The present invention relates to a method of enriching a pathogen using an homobifunctional imidoester group, and the method of enriching a pathogen and extracting nucleic acids using homobifunctional imidoester compound (DMA, DMP, DMS) according to the present invention can quickly extract a small amount of pathogen contained in a sample without the use of special equipment and can be used as in situ diagnosis, and since it is possible to enrich a pathogen and extract nucleic acids simultaneously in one tube or a chip, it has the advantage of being more efficient than the conventional method, saving time and cost, and being easy to use.

Abstract: This disclosure is directed to ophthalmic suspension vehicles for delivery of at least one pharmaceutical ingredient to a patient in need of treatment. The disclosure also provides methods of delivering at least one pharmaceutical ingredient to a patient in need of treatment.

Abstract: Process for preparing a heat-treated pooled human platelet lysate, said process comprising the steps of: a) Providing a pooled human platelet lysate (p HPL), b) Heat-treating the pooled human platelet lysate at a temperature of 50° C. to 70° C. during 20 to 40 minutes, c) Purifying the heat-treated pooled human platelet lysate of step b).

Abstract: The present disclosure provides a method for extracting and separating flavonoids from Lindera aggregata leaves. The method includes: mixing Lindera aggregata leaves with an adsorbent, conducting elution with a matrix solid-phase dispersion (MSPD) extraction method, followed by concentration to obtain a Lindera aggregata leaf extract; conducting primary separation and secondary separation on the Lindera aggregata leaf extract by high-speed counter-current liquid chromatography (HSCCC), to separate quercetin-3-O-?-D-arabinofuranoside, a mixture of quercetin-3-O-?-D-glucoside and quercetin-5-O-?-D-glucoside, quercetin-3-O-rhamnopyranoside, and kaempferol-7-O-?-L-rhamnopyranoside; where a second solvent system used in the secondary separation includes ethyl acetate, n-butanol, an addictive and water, and the addictive includes cyclodextrin.

Abstract: The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

Abstract: Compositions and methods related to powdered hemostats that crosslink during and/or after application to a bleeding site are generally described.

Abstract: Provided is a method of preparing ferric carboxymaltose with weight average molecular weight between 100,000 and 400,000. The method includes reacting an oxidized maltodextrin solid with an iron (III) salt solution in acidic and basic conditions in sequence to afford ferric carboxymaltose, wherein the oxidized maltodextrin solid has a dextrose equivalent of less than 4. The ferric carboxymaltose prepared by the method can withstand high-temperature sterilization with high stability and facilitate storage.

Abstract: Embodiments of the present application relate to polymers for liquid phase oligonucleotide synthesis. Methods for making an oligonucleotide by liquid phase oligonucleotide synthesis, comprising dissolving a polyvalent hub having a plurality of functional groups in a solvent and contacting the polyvalent hub with one or more nucleoside analogs to form a first bioconjugate are also provided.

Abstract: For the isolating of nanocrystals from a lignocellulose- or chitin-containing starting material, the starting material is exposed to an oxidative effect of periodate anions in an aqueous suspension. The pH value of the aqueous suspension is adjusted to greater than pH 7.0. The periodate anions are provided in a quantity of at least 5 mol per kg of the starting material, and the starting material is exposed to the oxidative effect of the periodate anions in the aqueous suspension for a period of at least one day.

Abstract: There are provided compounds of Formula (A) and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for the prevention or treatment in a mammal of joint and bone disorders such as arthritis and osteoporosis.

Abstract: Disclosed are aminocoumarin compounds, pharmaceutical compositions containing aminocoumarin compounds, and methods of their use, e.g., in the treatment of a Gram-negative bacterial infection.

Abstract: A compound of formula I: or a salt thereof, wherein: R1 is —OC(H)(X)(CH2)nC(?O)OH; R2 is —OH, —N3, or —N(H)C(?O)CH3; or R1 and R2 together with the carbon atoms to which they are attached form R3 is —H, —CH3, —CH2C(?O)OH, or —CH2OH; X is —H, —CH3, —CH2OH, or CH2C(?O)OH; and n is 0 or 1.